Patent US5654337A successfully refreshed from Google Patents.
US5654337A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical formulation for local delivery of a pharmaceutically active agent
Assignee: SPEED GEL Inc
•
Filing: 1995-03-24
•
Granted: 1997-08-05
•
Expires: 2015-03-24
Abstract
Abstract This invention relates to a composition useful in the delivery of pharmaceutically active agents through the skin. In one embodiment of the invention, the composition is formulated with a non-steroidal anti-inflammatory agent, such as ibuprofen or ketoprofen. Such formulation is rapidly absorbed through the skin to provide local relief from pain. In another embodiment of the invention, the composition is formulated with an antineoplastic agent. Such formulation is rapidly absorbed through the skin to provide local delivery to subcutaneous tumors. The composition is useful for transcutaneous delivery of other pharmaceutically-active compounds.
Inventors
- 👤 Elmer George Roentsch
- 👤 II William Scott Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 18:32
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K9/06; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K47/16; A61K47/18; A61K47/20; A61K47/24
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
91 words
A composition for the delivery of a pharmaceutically active substance through the skin of a mammal which comprises a biocompatible organic solvent, a polar lipid, a surfactant, water, urea and the pharmaceutically active substance to be delivered, at a pH of about 6.0 to 8.0, wherein the polar lipid is lecithin or phosphatidylcholine, the biocompatible organic solvent is an isopropyl ester, selected from the group consisting of isopropyl myristate and isopropyl palmitate, and the urea is present at a concentration of about 5 to 20% by mass of the final composition.
Claim 2
Dependent Claim
91 words
A composition for the delivery of a pharmaceutically active substance through the skin of a mammal which comprises a biocompatible organic solvent, a polar lipid, a surfactant, water, urea and the pharmaceutically active substance to be delivered, at a pH of about 6.0 to 8.0, wherein the polar lipid is lecithin or phosphatidylcholine, the biocompatible organic solvent is an isopropyl ester, selected from the group consisting of isopropyl myristate and isopropyl palmitate, and the urea is present at a concentration of about 5 to 20% by mass of the final composition.
Claim 3
Dependent Claim
12 words
The composition, according to claim 1, wherein the polar lipid is lecithin.
Claim 4
Dependent Claim
29 words
The composition, according to claim 2, wherein the surfactant is selected from the group consisting of docusate sodium, docusate sodium benzoate, docusate calcium, tween 80, polysorbate 80, and ibuprofen.
Claim 5
Dependent Claim
31 words
The composition, according to claim 1, wherein the pharmaceutically active substance is an analgesic, an anti-inflammatory, a biologically active protein, a cellulite reducer, a substance P antagonist, or an antineoplastic compound.
Claim 6
Dependent Claim
16 words
The composition, according to claim 4, wherein the pharmaceutically active substance is a non-steroidal anti-inflammatory agent.
Claim 7
Dependent Claim
15 words
The composition, according to claim 5, wherein the pharmaceutically active substance is ibuprofen or ketoprofen.
Claim 8
Dependent Claim
30 words
A composition comprising, as a percentage of the mass of the final composition: (a) Lecithin 10-30%; (b) isopropyl myristate 10-30%; (c) urea 5-20%; (d) water 30-60%; (e) a surfactant 10-20%.
Claim 9
Dependent Claim
30 words
A composition comprising, as a percentage of the mass of the final composition: (a) Lecithin 10-30%; (b) isopropyl myristate 10-30%; (c) urea 5-20%; (d) water 30-60%; (e) a surfactant 10-20%.
Claim 10
Dependent Claim
11 words
The composition, according to claim 7, further comprising about 1% nifedipine.
Claim 11
Dependent Claim
14 words
The composition, according to claim 7, further comprising about 5-10% ketoprofen, or 5-20% ibuprofen.
Claim 12
Dependent Claim
17 words
The composition, according to claim 7, further comprising about 2% lidocaine, 0.025-0.075% capsaicin P or 2% aminophylline.
Claim 13
Dependent Claim
11 words
The composition, according to claim 10, further comprising about 1% cyclobenzaprine.
Claim 14
Independent Claim
97 words
A method of making a composition for transcutaneous delivery of a pharmaceutically active substance which comprises: (a) dissolving a polar lipid in an about equal mass of biocompatible organic solvent; (b) adding a surfactant to the composition of step (a) to a concentration of about 10% to about 20%; (c) dissolving a pharmaceutically active compound in the solvent-polar lipid, surfactant mixture of step (b) to a concentration of about 0.01% to about 30%; (d) adding aqueous urea to a concentration of about 5% to about 20%; and (e) adjusting the pH to between about 6.0 to 8.0.
Claim 15
Independent Claim
97 words
A method of making a composition for transcutaneous delivery of a pharmaceutically active substance which comprises: (a) dissolving a polar lipid in an about equal mass of biocompatible organic solvent; (b) adding a surfactant to the composition of step (a) to a concentration of about 10% to about 20%; (c) dissolving a pharmaceutically active compound in the solvent-polar lipid, surfactant mixture of step (b) to a concentration of about 0.01% to about 30%; (d) adding aqueous urea to a concentration of about 5% to about 20%; and (e) adjusting the pH to between about 6.0 to 8.0.
Claim 16
Dependent Claim
10 words
A composition prepared according to the method of claim 12.
Claim 17
Dependent Claim
38 words
A composition consisting essentially of: lecithin 10-15%; isopropyl myristate 10-15%; docusate sodium 10-20%; urea 5-15%; and water 25-60%; and at least one pharmaceutically active ingredient present at between 0.01-30%, at a pH of between about 6.0 to 7.0.
Claim 18
Dependent Claim
38 words
A composition consisting essentially of: lecithin 10-15%; isopropyl myristate 10-15%; docusate sodium 10-20%; urea 5-15%; and water 25-60%; and at least one pharmaceutically active ingredient present at between 0.01-30%, at a pH of between about 6.0 to 7.0.
References Cited (Backward Citations)
US3154470A
Cited
FR2288515A1
Cited
US3957971A
Cited
US4385049A
Cited
US4794106A
Cited
US5016652A
Cited
JPS61260015A
Cited
US5045565A
Cited
WO1989000077A1
Cited
US4847069A
Cited
JPH01242521A
Cited
US5093133A
Cited
DE4021082A1
Cited
US5210099A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-08-04 | 2001-02-03 | 2001-08-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-08-04 | 2005-02-03 | 2005-08-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-08-04 | 2009-02-03 | 2009-08-05 | $7700.00 | Window Closed / Lapsed |